Support for Cura’s Project and Events

Cura has received grants to support its events and projects, including:

  • Grants from The Leona M. and Harry B. Helmsley Charitable Trust to support Cura’s Fifth International Vatican Conference – Exploring the Mind, Body and Soul – How innovation and Novel Delivery Systems Improve Human Health and Fourth International Vatican Conference – Unite To Cure – How Science, Technology and 21st Century Medicine Will Impact Culture and Society; and
  • A grant from the John Templeton Foundation to support the Bridging Science and Faith Project, which created a unique forum where prominent speakers with backgrounds in science, medicine, theology and philosophy can explore the role of religion, faith and spirituality in health and wellbeing, as well as the relationship between the mind, body and soul.

Our Grantors

John Templeton Foundation

Founded in 1987, the John Templeton Foundation supports research and dialogue on the deepest and most perplexing questions facing humankind. The Foundation funds work on subjects ranging from black holes and evolution to creativity, forgiveness, and free will. It also encourages civil, informed dialogue among scientists, philosophers, theologians, and the public at large.

With over $2.8 billion in assets and annual grants of $115 million in 2018, the Foundation ranks among the 25 largest grantmaking foundations in the United States. Headquartered outside Philadelphia, its philanthropic activities have engaged all major faith traditions and extended to more than 190 countries around the world.

Learn more about the John Templeton Foundation.

The Leona M. and Harry B. Helmsley Charitable Trust

The Leona M. and Harry B. Helmsley Charitable Trust, is a global philanthropy committed to helping people live better lives today and creating stronger, healthier futures for individuals and communities. Our Type 1 Diabetes (T1D) Program is dedicated to helping the global T1D community live safer, better, and more fulfilling lives today while funding advancements in research and technology for a better tomorrow.

T1D is an autoimmune disease, and the only one requiring day-to-day management that includes regular dosing decisions with a drug (insulin) that can cause death. It’s a lifelong condition that poses significant burdens on individuals, their loved ones, and on health systems in the United States and around the world. Current access to care and existing therapies falls short of easing these burdens, and incrementalism is not an option. Helmsley invests in ideas that have the potential for significant impact. We embrace high-risk efforts, led by dedicated leaders who will be partners and share our vision.

For additional information, please visit: